Emmaus Life Sciences Secures Exclusive Supply Agreement for Endari® with NeoImmuneTech
EMMA filed a M&A and Partnerships on light trading volume (0.3× avg).
Summary
Emmaus Life Sciences signed an exclusive supply agreement with NeoImmuneTech for Endari® in North America, with terms including a double-digit margin, though its effectiveness is contingent on regulatory approvals.
Key Events · M&A and Partnerships · EMMA
-
Exclusive Supply Agreement Signed
Emmaus Life Sciences and NeoImmuneTech, Inc. (NIT) entered into an Exclusive Supply Agreement on March 2, 2026, for Endari® in the U.S. and Canada.
-
Favorable Supply Terms
Emmaus will exclusively supply Endari® to NIT, and NIT will exclusively purchase from Emmaus, at a price based on Emmaus's cost of production plus a specified double-digit percentage margin.
-
Contingent Effective Date
The agreement's 'Effective Date' is subject to NIT obtaining necessary regulatory approvals and licensing, with no assurance it will occur by the October 1, 2026 deadline.
-
Follows Prior License Agreement
This supply agreement was contemplated by a License and Exclusive Distribution Agreement dated December 24, 2025, previously reported on December 31, 2025.
Analysis · EMMA · Life Sciences
Emmaus Life Sciences has entered into an exclusive supply agreement with NeoImmuneTech (NIT) for its sickle cell disease product, Endari®, in the U.S. and Canada. This agreement, which was contemplated by a prior license agreement from December 2025, establishes Emmaus as the sole supplier to NIT at a purchase price based on production cost plus a double-digit percentage margin. While this deal could provide a stable revenue stream and distribution channel for Emmaus, its effectiveness is contingent upon NIT obtaining necessary regulatory approvals and licensing by October 1, 2026, introducing a degree of uncertainty.
At the time of this filing, EMMA was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $926.1K. The 52-week trading range was $0.00 to $0.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.